Every 8-K that Myomo Inc. (MYO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow MYO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYO filings page.
Myomo, Inc. reported second quarter 2026 revenue of $11.7 million, a 21% increase from a year earlier, driven by higher average selling prices and 211 MyoPro units recognized. Gross margin rose to 72.1% from 62.7% as cost reductions and pricing offset higher clinical costs.
Operating expenses were $10.7 million, up less than 1%, leading to an operating loss of $2.3 million versus $4.6 million last year. Net loss was $4.0 million, or $0.09 per share, including a $1.2 million non-cash derivative liability charge, while Adjusted EBITDA loss improved to $0.8 million from $4.0 million. Cash, cash equivalents and short-term investments totaled $13.5 million, with cash used in operating activities reduced to $1.9 million from $8.9 million. Management now expects third quarter 2026 revenue of $11.5 million to $12.0 million and has raised full-year 2026 revenue guidance to $45 million to $47 million, while reiterating expectations for operating leverage and lower second-half cash burn.
Myomo, Inc. filed an amended current report to correct exhibit labels and hyperlinks in a prior 8-K, with no changes to the underlying actions. At the June 25, 2026 Annual Meeting, stockholders approved an amendment to the 2018 Stock Option and Incentive Plan, increasing shares available under the plan by 1,833,000.
Stockholders also approved a Charter Amendment increasing authorized common stock to 100,000,000 shares, which became effective upon filing with Delaware on June 25, 2026. As of April 29, 2026, 38,638,669 common shares were outstanding and entitled to vote. All proposals on the agenda, including director elections, executive compensation on an advisory basis, auditor ratification, a stockholder proposal on director classification, and the ability to adjourn the meeting, received the requisite support.
Myomo, Inc. reported results from its June 25, 2026 Annual Meeting of Stockholders, where several governance and capital structure changes were approved. Stockholders adopted an amendment to the company’s 2018 Stock Option and Incentive Plan, adding 1,833,000 shares available for equity awards.
They also approved a Charter Amendment increasing the authorized number of common shares to 100,000,000, which became effective upon filing in Delaware on June 25, 2026. As of April 29, 2026, 38,638,669 common shares were outstanding and entitled to vote.
Shareholders elected two Class III directors, approved an advisory vote on executive compensation, ratified CBIZ CPAs P.C. as auditor for 2026, supported a stockholder proposal on director classification, and authorized potential adjournments to solicit additional proxies if needed.
Myomo, Inc. appointed Joseph M. (Joe) Manko Jr. to its Board of Directors effective May 9, 2026. He will serve as a Class I director until the 2027 annual meeting of stockholders, when he will be eligible for election by shareholders.
Manko, age 60, is Senior Principal of Horton Capital Management LLC, a significant Myomo shareholder, and brings more than 25 years of experience across investment banking, private equity, asset management and corporate strategy. With his appointment, Myomo’s Board now has seven directors.
He will receive the same compensation as other non-employee directors beginning after the 2026 annual meeting, currently an annual cash retainer of $60,000 and an annual grant of restricted stock units with a grant date fair value of $85,000. He has entered into a standard indemnification agreement with the company, and there are no related-party transactions requiring disclosure.
Myomo, Inc. reported first quarter 2026 revenue of $10.1 million, up 3% from a year earlier, driven by a higher average selling price and a growing mix of recurring patient sources, which rose to 49% of revenue versus 25% in the prior-year quarter.
Gross margin improved to 68.2% and operating expenses fell 1%, narrowing the net loss to $3.0 million, or $0.07 per share. Management expects second quarter 2026 revenue of $10.3 million to $10.8 million and reaffirmed full-year 2026 revenue guidance of $43 million to $46 million, citing a larger backlog and expanding in-network payer access.
Myomo, Inc. appointed William “Will” Febbo to its Board of Directors effective April 14, 2026, as a Class II director serving until the 2028 annual meeting, bringing over 30 years of experience in healthcare, financial services, and technology-driven businesses.
As a non-employee director, he was granted 45,000 restricted stock units (RSUs) that vest on the first anniversary of his appointment. He will also receive an annual cash retainer of $60,000 and an additional $85,000 per year in RSUs vesting quarterly. The company highlighted his prior leadership at OptimizeRx, where revenue expanded from $5 million to $92 million with a five-year CAGR of 41%, and his capital markets background as important additions to Myomo’s board.
Myomo, Inc. reported fourth quarter 2025 revenue of $11.4 million, down 6% from 2024, while full-year 2025 revenue grew 26% to $40.9 million. Q4 gross margin was 68.6%, and full-year gross margin was 65.7%, both below 2024 levels.
The company’s net loss widened to $3.8 million in Q4 2025 and $15.6 million for the year, compared with losses of $0.3 million and $6.2 million in 2024. Cash, cash equivalents and short-term investments totaled $18.4 million as of December 31, 2025.
Recurring patient sources, including O&P providers and referrals from the MyoConnect program, accounted for 42% of Q4 revenue versus 26% a year earlier, supported by a record 241 MyoPro orders. For 2026, Myomo expects revenue of $43 million to $46 million and aims to cut negative free cash flow by roughly half compared with 2025.
Myomo, Inc. disclosed that its Compensation Committee approved a 2026 salary-for-restricted stock unit program open to all salaried employees. CEO Paul Gudonis and CFO David Henry each voluntarily elected to reduce their 2026 base salary by 10% in exchange for RSUs with an aggregate grant date fair value equal to 115% of the salary foregone, or $40,000 for the CEO and $30,000 for the CFO.
The company may, in its sole discretion, terminate or modify this program at any time before January 12, 2026; if it does, no RSUs will be granted and base salaries will remain unchanged. Subject to that right, RSUs will be granted in equal quarterly installments beginning January 12, 2026, with each quarterly grant vesting in full three months after its grant date under the company’s 2018 Stock Option and Incentive Plan and the applicable RSU agreements, provided the officer remains in continuous service.
Myomo, Inc. entered a new senior secured Loan and Security Agreement with Avenue on November 4, 2025, providing committed term loans of up to $17.5 million. The company received $12.5 million at closing (Tranche 1), with up to $5.0 million available between November 4, 2026 and May 4, 2027, subject to no default. By mutual agreement, a discretionary tranche could add up to $10.0 million in 2027. The loans bear interest at 4.75% + WSJ prime (with a prime floor set on the closing date) and mature on June 1, 2029. Interest-only runs for 18 months after closing, extendable six months if Tranche 2 funds. The facility is secured by a senior lien on all assets, including IP.
Prepayment fees are 3.0%/2.0%/1.0% by anniversary, plus a 3.25% final payment fee at maturity or earlier prepayment. Covenants require at least $2.5 million of unrestricted cash, achieving ≥75% of trailing three‑month projected revenue, and limiting trailing six‑month cash burn to the greater of 150% of projected or $2.0 million. The lender may convert up to $3.0 million of Tranche 1 and $1.0 million of Tranche 2 into common stock at 120% of the warrant exercise price and holds a $1.0 million equity participation right. Myomo also issued a warrant to purchase up to $1,312,500 worth of common stock, exercisable at the lesser of $0.96 or the next bona fide equity round price before June 30, 2026, expiring November 4, 2030. A Q3 2025 results press release was furnished as Exhibit 99.1.
Myomo, Inc. (MYO) reported that it announced its financial results for the second quarter ended June 30, 2025 and furnished the full press release as Exhibit 99.1 to this Current Report on Form 8-K filed August 11, 2025. The filing clarifies that the press release is furnished and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other securities filings unless specifically referenced. The report is signed by Chief Financial Officer David A. Henry. No earnings figures, revenue amounts, or other numerical financial details are included in the body of this 8-K.